Unlocking the full potential of membrane proteins.
Membrane proteins are among the most valuable drug targets in the pharmaceutical industry, with more than 60% of approved drugs acting on membrane-embedded proteins. Yet their intrinsic instability outside the native membrane environment remains a fundamental challenge, significantly complicating drug discovery and development efforts.
To address this challenge, GIOS Biostructures has developed a proprietary technology, the MESO-platform, which stabilizes essential membrane proteins into a next-generation nanodisc, called MESOdisc™. The MESO-platform enables streamlined and improved workflows for the development of therapeutic antibodies, peptides and small-molecule drugs targeting membrane proteins.
With our technology we go from undruggable to cornerstone, unlocking the full potential of membrane proteins.
MESOdiscs™
next-generation nanodiscs
The MESO-platform™ allows membrane proteins to be expressed and studied without incorporation into the cell membrane. This approach produces stable, soluble MESOdiscs™, facilitating drug target discovery and drug development. A major advantage is the ability to lock proteins in a specific conformational state while maintaining their native structure.
MESOdisc™ applications
The MESO-platform™ enables membrane protein reconstitution suitable for a wide variety of downstream analytical and functional applications.